The Nomination Committee of Flerie AB proposes the election of an additional Board member
The Nomination Committee of Flerie AB (publ) has submitted a revised proposal for resolution to the Annual General Meeting on 26 March 2026. The change concerns the Nomination Committee’s proposal to elect Holger Kissel as a new member of the Board of Directors.
Dr. Holger Kissel is a senior biotech executive with more than 20 years of experience in scientific research, business development, industry-industry collaboration as well as public-private partnerships. He has worked at BioNTech SE since 2013 and currently serves as Senior Vice President, Scientific Relations & Liaison. Holger Kissel has led major pharma collaborations of BioNTech such as with Pfizer, Genentech, Sanofi, as well as with organizations like Coalition for Epidemic Preparedness Innovations, Gates Foundation, and the European Commission, and played a key role in the alliance management of the Comirnaty COVID-19 vaccine collaboration between BioNTech and Pfizer. Before joining BioNTech, he held leadership roles at TaconicArtemis and conducted postdoctoral research at The Rockefeller University.
Holger Kissel is considered independent of Flerie, its management and its major shareholders.
The Nomination Committee’s revised proposal means that the Board of Directors shall consist of five members, with the re-election of the current Board members Thomas Eldered, Cecilia Edström, Anders Ekblom and Jenni Nordborg and the new election of Holger Kissel.